Peer-reviewed veterinary case report
Carboplatin chemo after surgery for dogs with mouth melanoma
By Dank, G et al.·Published in Veterinary and comparative oncology·2014·Koret School of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision.
- Species:
- dog
Plain-English summary
A group of 17 dogs with oral malignant melanoma, a common type of mouth cancer, received a chemotherapy drug called carboplatin after having their tumors surgically removed. The dogs were given an average of four doses of carboplatin, and the results showed that most dogs lived for about 440 days after treatment. However, many experienced local recurrence or spread of the cancer during that time. This suggests that carboplatin could be a helpful addition to surgery for treating this aggressive cancer, but more research is needed to confirm the best treatment options.
People also search for: dog oral melanoma treatment · carboplatin for dogs cancer · dog mouth tumor survival rate
Abstract
Melanoma is the most common oral malignancy in dogs. This retrospective study evaluated adjuvant carboplatin chemotherapy (with or without radiation therapy) in 17 dogs with malignant oral melanoma following surgical resection. The median dosage and number of doses of carboplatin administered to the 17 dogs was 300 mg m(-2) (range, 150-300 mg m(-2)) and 4 (range, 2-11), respectively. The overall median progression-free survival for all dogs was 259 days [95% confidence interval (CI95), 119-399 days]. The first progression-free survival event was local recurrence in seven dogs (41%) and metastases in seven dogs (41%). The median overall survival for all dogs was 440 days (CI95, 247-633 days). The tumour was the cause of death in 10 dogs (59%). On the basis of this study, systemic therapy with carboplatin may be an appropriate adjunct to local treatment for canine malignant melanoma, although future prospective controlled studies are needed to compare treatment modalities for this aggressive neoplasia.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22737988/